ClinicalTrials.gg
RecruitingNCT06818084TRAMPERSUpdated Jan 30, 2026

TRanscAtheter TreatMent of PurE Aortic Regurgitation With VitaFlow Liberty System

A Phase 4 interventional study of VitaFlow+GDMT and J-Valve+GDMT in AORTIC VALVE DISEASES, Aortic Regurgitation and Transcatheter Aortic Valve Replacement (TAVR), sponsored by Ruijin Hospital. Recruiting at 4 sites in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Primary conditionAortic Valve InsufficiencyRegistry: Aortic Valve DiseaseReclassifiedWhy we changed it
Registry
Aortic Valve Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Aortic Valve Insufficiency
Why
  1. The study's listed conditions name Aortic Valve Insufficiency, a narrower term within Aortic Valve Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ruijin Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Aortic Valve Insufficiency with a site in China — 17 open to participants now, 17 under way, none of them phase 3. Aortic Valve Insufficiency · China.

Planned enrollment
5th of 11
120 · median 116
Started
2025
with 5 others
Phase 4
Only one
of the 23
Primary completion
2027-11
later than 6 of 16 live
Registered
11th of 23
by date
Lead sponsor
2 of 23
Ruijin Hospital

Among the 23 studies in Aortic Valve Insufficiency with a site in China, this one is the 5th largest by planned enrollment of the 11 interventional ones that give a count, is one of 6 that started in 2025, is the only one in phase 4, reaches primary completion later than 6 of the 16 other live ones, and was the 11th registered.

Aortic Valve Insufficiency

171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.

Browse Aortic Valve Insufficiency studies →

Open to participants now

17 of the 23 studies in Aortic Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 39 Aortic Valve Insufficiency studies recruiting now, 31 (79%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Aortic Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

This study is a prospective, multicenter, non-randomized controlled trial, planning to enroll 180 patients with pure native aortic regurgitation. On the basis of standardized medical therapy, patients will be assigned in a 1:1 ratio to undergo transfemoral transcatheter aortic valve replacement (TF-TAVR) . This prospective, multicenter trial aims to evaluate the safety and effectiveness of transfemoral TAVR using the VitaFlow™ self-expanding valve system compared to dedicated transcatheter devices in patients with PNAR.

The primary endpoint is a composite of all-cause mortality, disabling stroke, and rehospitalization for heart failure, myocardial Infarction, and requiring dialysis or valve reoperation at 12 months post-procedure.

Secondary endpoints include procedure-related complications, long-term clinical events, patient functional status and quality of life, bioprosthetic valve imaging follow-up, echocardiographic parameters, and treatment costs. All endpoint definitions conform to the Valve Academic Research Consortium-3 (VARC-3) criteria

Read the detailed description

The purpose of this study is to evaluate the safety and efficacy of TF-TAVR for the treatment of isolated aortic regurgitation. The study will compare all-cause mortality, cardiovascular mortality, stroke, rehospitalization for heart failure, and renal failure requiring dialysis treatment at 12 months after TAVR. Additionally, the study will assess the incidence of hypoattenuated leaflet thickening (HALT) and reduced leaflet motion (RLM) via CTA, as well as the aortic valve root-prosthesis coaxiality. Changes and differences between groups in the following parameters will be evaluated using transthoracic echocardiography at 6 and 12 months after enrollment: left ventricular ejection fraction (Simpson method), left ventricular end-diastolic volume index (LVEDVi), left ventricular end-systolic volume index (LVESVi), left ventricular end-diastolic diameter (LVEDd), left ventricular end-systolic diameter (LVESd), estimated aortic valve orifice area, valvular regurgitation, and transvalvular pressure gradient compared with baseline. The study will also compare changes and differences between groups in the Minnesota Living with Heart Failure Questionnaire, Social Support Rating Scale (SSRS), International Physical Activity Questionnaire (IPAQ), and 6-minute walk test (6MWT) at 6 and 12 months after enrollment compared with baseline. Furthermore, the study will compare surgical costs, potential complication costs, and disease-related costs between the two groups.

03

Conditions studied

  • AORTIC VALVE DISEASES
  • Aortic Regurgitation
  • Transcatheter Aortic Valve Replacement (TAVR)

Browse trials for

Keywords

  • pure aortic regurgitation
  • Transcatheter aortic valve replacement (TAVR)
  • hypoattenuated leaflet thickening
  • reduced leaflet motion
04

In context

Aortic Valve Insufficiency Reclassified

171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.

This study's planned enrollment of 120 is close to the median of 123 across 92 interventional studies indexed under Aortic Valve Insufficiency.

Browse Aortic Valve Insufficiency studies →

Lead sponsor

Ruijin Hospital is the lead sponsor of 682 studies on the registry; 389 are open to participants now.

Compared within Aortic Valve Insufficiency, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Aortic Valve Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Age ≥ 60 years. Symptomatic moderate-to-severe or greater isolated aortic regurgitation.

Asymptomatic moderate-to-severe or greater isolated aortic regurgitation meeting at least one of the following criteria:

≤ 55% (measured by biplane Simpson's method); LVESD > 50 mm ; LVESDi > 22 mm/mm²; LVESVi > 45mL/m2 Anatomical suitability for TAVR as assessed by the heart team. Provision of written by the patient or their legal guardian, with agreement to the treatment plan and willingness and ability to comply with all required follow-up assessments.

Exclusion Criteria Incomplete coronary revascularization. Less than 30 days of guideline-directed medical therapy at maximally tolerated doses.

\< 1 year. LVEF \< 45%. \< 30 mL/min/1.73m². Known allergy or to required medications (e.g., aspirin, clopidogrel, warfarin) or contrast media.

Any condition that precludes contrast-enhanced CT. Concurrent moderate-to-severe or severe valvular heart disease other than aortic regurgitation.

Poor patient compliance, unable to complete follow-up as required. Any other condition that, in the investigator's judgment, would make the patient unsuitable for the study.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    VitaFlow

    Patients who meet the inclusion and exclusion criteria will undergo TAVR using the VitaFlow™ self-expanding valve system.

    Combination Product: VitaFlow+GDMT

  • Active comparator
    J-Valve

    Patients who meet the inclusion and exclusion criteria will undergo TF-TAVR using dedicated transcatheter device J-Valve system.

    Combination Product: J-Valve+GDMT

Interventions

  • Combination productVitaFlow+GDMT

    The patient will undergo transcatheter aortic valve replacement on the basis of guideline-directed medical therapy with The VitaFlow™ system. The VitaFlow™ system (MicroPort®, Shanghai, China) was a novel TAVR system, which incorporates high-radial force and a double layer polyethylene terephthalate (PET) skirt to optimize frame geometry and minimize the risks of paravalvular leak (PVL). The VitaFlow™ transcatheter aortic valve is made of a self-expanding nitinol frame and tri-leaflet bovine pericardial valve.

  • Combination productJ-Valve+GDMT

    The patient will undergo transfemoral aortic valve replacement on the basis of guideline-directed medical therapy with The J-Valve system (Jie ChengMedical Technologies, Suzhou, China). The J-Valve system is a second-generation self-expand able device composed of a porcine bioprosthetic aortic valve and a transfemoral delivery sheath. The valve is supported by a self-expanding nitinol structure. The different valve sizes are 21, 23, 25, 27, 29 and 34 mm. Three U-shaped nitinol graspers were designed to surround the valve.

07

What researchers measure

Primary outcomes

  1. Clinical worsening

    The primary endpoint is a composite of all-cause mortality, disabling stroke, and rehospitalization for heart failure, myocardial Infarction, and requiring dialysis or valve reoperation at 12 months post-procedure.

    Time frame: 12 months

Secondary outcomes

  1. Rate of procedural complications

    The rate of any aortic dissection, annular rupture, coronary artery occlusion, vascular complications, permanent pacemaker implantation, reoperation of heart valve.

    Time frame: 12 months

  2. 6-minute walk distance

    This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes.

    Time frame: 12 months

  3. New York Heart Association (NYHA) functional class

    Classification of function capacity of the NYHA.

    Time frame: 12 months

  4. Rate of hypoattenuated leaflet thickening

    The rate of hypoattenuated leaflet thickening. Hypoattenuated leaflet thickening(HALT)defined by VARC-3

    Time frame: 12 months

  5. Rate of reduced leaflet motion

    Rate of reduced leaflet motion. Reduced leaflet motion(RLM)defined by VARC-3.

    Time frame: 12 months

  6. Rate of Stroke

    Stroke is defined as an acute episode of focal or global neurological dysfunction caused by the brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction.

    Time frame: 12 months

  7. Mortality

    All-cause, cardiovascular, and non-cardiovascular mortality

    Time frame: 12 months

  8. Rate of bleeding complications

    Rate of bleeding complications. The original VARC definitions with BARC classifications

    Time frame: 12 months

  9. Rate of prothetic valve dysfunction

    The rate of any prothetic aortic valve stenosis, prothesis-patient mismatch, prosthetic aortic valve regurgitation

    Time frame: 12 months

  10. Rate of rehospitalization

    The rate of rehospitalization due to valve-related symptoms or worsening congestive heart failure.

    Time frame: 12 months

  11. Quality of life assessment (Minnesota Living with Heart Failure Questionnaire, MLHFQ)

    Total score of Minnesota Living with Heart Failure Questionnaire (MLHFQ). The total score ranges from 0 to 105, with higher scores indicating a greater impact of heart failure on quality of life and worse outcome..

    Time frame: 12 months

  12. Quality of life assessment (social supporting raing scal, SSRS)

    Total score of social supporting raing scal (SSRS). The total score ranges from 0 to 40, with higher scores indicating a higher level of social support.

    Time frame: 12 months

  13. Quality of life assessment (International Physical Activity Questionnaire, IPAQ)

    Total score of International Physical Activity Questionnaire (IPAQ). The total score is calculated by multiplying the frequency and duration of each activity by its respective MET value, and then summing these products. The result is a measure of the total energy expenditure from physical activity in MET-minutes per week.The total score can be used to classify individuals into different physical activity levels, such as low, moderate, or high.

    Time frame: 12 months

  14. Treatment costs

    Including surgical costs, potential complications costs, and disease-related costs

    Time frame: 12 months

Other outcomes

  1. Left ventricular ejection fraction (Simpson's method)

    Transthoracic echocardiography measurement of left ventricular ejection fraction (Simpson's method). Unit: %

    Time frame: 12 months

  2. Left ventricular end-diastolic volume index

    Transthoracic echocardiography measurement left ventricular end-diastolic volume index (LVEDVi). Unit: milliliters per square meter (mL/m²)

    Time frame: 12 months

  3. Left ventricular end-systolic volume index

    Transthoracic echocardiography measurements of left ventricular end-systolic volume index (LVESVi). Unit: milliliters per square meter (mL/m²)

    Time frame: 12 months

  4. Left ventricular end-diastolic diameter

    Transthoracic echocardiography measurements of left ventricular end-diastolic diameter (LVEDd). Unit: millimeters

    Time frame: 12 months

  5. Left ventricular end-systolic diameter

    Transthoracic echocardiography measurements of left ventricular end-systolic diameter (LVESd). Unit: millimeters

    Time frame: 12 months

  6. Aortic valve orifice area

    Transthoracic echocardiography measurement of aortic valve orifice area. Unit: square centimeters

    Time frame: 12 months

  7. Transvalvular pressure gradient of aortic valve

    Transthoracic echocardiography measurement of transvalvular pressure gradient of aortic valve. Unit: mmHg

    Time frame: 12 months

08

Study locations

4 of 4 sites recruiting
09

References and documents

Publications

  • Yu J, Zhu N, Zhu L, Pan X, Zhu Z; TRAMPERS investigators. Transcatheter treatment of pure aortic regurgitation with the VitaFlowTM Liberty system: design & rationale of the prospective, multicenter, non-randomized TRAMPERS study. Future Cardiol. 2026 Mar;22(3):229-236. doi: 10.1080/14796678.2026.2632486. Epub 2026 Feb 25. PubMed 41739727 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Nov 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2025
First posted
Feb 10, 2025
StartActual
Apr 29, 2025
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06818084
Lead sponsor
Ruijin Hospital
Responsible party
Zhu zhengbin (Principal Investigator, Ruijin Hospital) — Principal investigator
First posted
Feb 10, 2025
Start date
Apr 29, 2025
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Jan 30, 2026

Study contacts

Zhengbin Zhu, MD. PhD.
Contact
zzb11561@rjh.com.cn
0086-15601950612
Jiwei Yu, MD
Contact
yjw12506@rjh.com.cn
0086-13761292857
ZhengBin Zhu, MD. PhD
principal investigator · Ruijin Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion